Hanmi Pharm announces a Chinese sales license agreement of new lung cancer treatment with ZAI Lab
On the 23rd, Hanmi Pharm(CEO Kwan-soon Lee) announced an exclusive license agreement to handle the self-developed targeted lung cancer treatment(HM61713) across China(including Hong Kong and Macao) with ZAI Lab, a Chinese life science company.
With the agreement, ZAI Lab acquired an exclusive li...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
